Cell Line News and Research

RSS

Discovery of new receptor that interacts with SARS-CoV-2 spike, suppresses infection

Researchers recently conducted a study to identify host factors affecting cellular interactions of the SARS-CoV-2 spike protein.

16 Nov 2021

Cell-based viral replication system for screening of SARS-CoV-2 drugs

The current study reports a SARS-CoV-2 replicon system within stable cell lines that can be cultured with ease in a standard biosafety level 2 laboratory.

10 Nov 2021

SARS-CoV-2 infection regulates protein arginylation

A new study explores the role of arginylation during SARS-CoV-2 infection.

9 Nov 2021

Waters and Sartorius partner to help bioprocess scientists accelerate clone selection and process development

Waters Corporation and Sartorius announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.

From Sartorius 3 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

The researchers investigated the neutralizing activity of turmeric root extract, curcumin-containing capsules, and pure curcumin against SARS-CoV-2.

1 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Sphere Fluidics announced today that it has closed a $40 million (circa £30 million) investment round.

From Sphere Fluidics 28 Oct 2021

Study finds SARS-CoV-2 infection is proportional to cell surface ACE2 levels

Researchers from Oregon State University have developed a system to assess the ability of SARS-CoV-2 to bind to ACE2 orthologs.

26 Oct 2021

Researchers develop ferritin-based nanomedicine for targeted delivery of leukemia therapy

Researchers from the Institute of Process Engineering\ of the Chinese Academy of Sciences, Peking University and Zhujiang Hospital of Southern Medical University have developed a ferritin (Fn)-based nanomedicine for targeted delivery of arsenic (As) and efficient therapy against diverse leukemia types.

25 Oct 2021

Study finds FDA-approved drug has potent antiviral activity against SARS-CoV-2 and variants of concern

A new study aimed to examine the antiviral potential of atovaquone against the original SARS-CoV-2 strain and other variants of concern.

25 Oct 2021

Replication of SARS-CoV-2 variants in different cell and organ models

In this study, the replication of B.1.1.7 viruses was analyzed in different cell and organ models and dwarf hamsters.

22 Oct 2021

Enisamium shows potential as antiviral therapy for COVID-19

Researchers studied the effect of enisamium on the growth and proliferation of Caco-2 and normal human bronchial epithelial cells.

6 Oct 2021

SARS-CoV-2 emerging variants display enhanced syncytia formation

Researchers compared the replication and syncytia forming potential of Alpha, Beta, and D614G strains in human cell lines and primary airway cells.

6 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Mandatory vaccines for health care workers might upend nurses’ training

Kaitlyn Hevner expects to complete a 15-month accelerated nursing program at the University of North Florida in Jacksonville in December. For her clinical training this fall, she's working 12-hour shifts on weekends with medical-surgical patients at a hospital.

4 Oct 2021

New analysis reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Oncotarget published "Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells" which reported that to ascertain phenotypical differences between these two distinct culture conditions, these authors carried out a comparative proteomic analysis of a membrane fraction obtained from 3D- and 2D-cultured NSCLC model cell line NCI-H23.

29 Sep 2021